Rothschild Investment LLC Sells 105,363 Shares of Novo Nordisk A/S $NVO

Rothschild Investment LLC cut its position in shares of Novo Nordisk A/S (NYSE:NVO) by 87.2% during the 2nd quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 15,477 shares of the company’s stock after selling 105,363 shares during the quarter. Rothschild Investment LLC’s holdings in Novo Nordisk A/S were worth $1,068,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in NVO. Revolve Wealth Partners LLC boosted its stake in shares of Novo Nordisk A/S by 8.7% in the 4th quarter. Revolve Wealth Partners LLC now owns 2,490 shares of the company’s stock worth $214,000 after buying an additional 200 shares during the last quarter. Kingsview Wealth Management LLC lifted its holdings in Novo Nordisk A/S by 9.3% during the first quarter. Kingsview Wealth Management LLC now owns 5,404 shares of the company’s stock worth $375,000 after acquiring an additional 461 shares during the period. Kestra Private Wealth Services LLC boosted its position in Novo Nordisk A/S by 22.4% in the first quarter. Kestra Private Wealth Services LLC now owns 59,531 shares of the company’s stock worth $4,134,000 after purchasing an additional 10,891 shares during the last quarter. OneAscent Financial Services LLC boosted its position in Novo Nordisk A/S by 75.7% in the first quarter. OneAscent Financial Services LLC now owns 9,306 shares of the company’s stock worth $644,000 after purchasing an additional 4,010 shares during the last quarter. Finally, J.W. Cole Advisors Inc. grew its stake in Novo Nordisk A/S by 58.3% in the 1st quarter. J.W. Cole Advisors Inc. now owns 16,266 shares of the company’s stock valued at $1,129,000 after purchasing an additional 5,989 shares during the period. Hedge funds and other institutional investors own 11.54% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities research analysts have recently commented on the company. UBS Group cut Novo Nordisk A/S from a “buy” rating to a “neutral” rating in a research note on Tuesday, August 5th. Morgan Stanley lowered shares of Novo Nordisk A/S from an “overweight” rating to an “underweight” rating and lowered their price objective for the stock from $59.00 to $47.00 in a research report on Monday, September 29th. Berenberg Bank raised shares of Novo Nordisk A/S from a “hold” rating to a “buy” rating in a research report on Wednesday, September 17th. Wall Street Zen lowered shares of Novo Nordisk A/S from a “buy” rating to a “hold” rating in a research note on Saturday, August 2nd. Finally, BNP Paribas upgraded Novo Nordisk A/S from an “underperform” rating to a “neutral” rating in a research note on Wednesday, August 13th. Two analysts have rated the stock with a Strong Buy rating, six have given a Buy rating, nine have given a Hold rating and three have assigned a Sell rating to the stock. According to data from MarketBeat.com, the stock has an average rating of “Hold” and an average target price of $59.20.

Novo Nordisk A/S Trading Up 0.5%

Shares of Novo Nordisk A/S stock opened at $48.52 on Tuesday. The company’s 50-day moving average price is $54.44 and its 200-day moving average price is $60.85. The company has a current ratio of 0.78, a quick ratio of 0.56 and a debt-to-equity ratio of 0.52. The company has a market cap of $216.63 billion, a price-to-earnings ratio of 13.33, a PEG ratio of 2.33 and a beta of 0.65. Novo Nordisk A/S has a 12-month low of $45.05 and a 12-month high of $112.52.

Novo Nordisk A/S (NYSE:NVO) last announced its quarterly earnings results on Wednesday, November 5th. The company reported $1.02 EPS for the quarter, beating the consensus estimate of $0.77 by $0.25. Novo Nordisk A/S had a net margin of 35.60% and a return on equity of 78.64%. The firm had revenue of $11.74 billion during the quarter, compared to the consensus estimate of $11.98 billion. Novo Nordisk A/S has set its FY 2025 guidance at EPS. On average, equities analysts expect that Novo Nordisk A/S will post 3.84 earnings per share for the current fiscal year.

About Novo Nordisk A/S

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.